Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 16/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1393856 | 0.99 | DPP4 (0.67) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL5038240 | 0.80 | DPP4 (0.44) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL3845530 | 0.79 | DPP4 (0.72) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL3845270 | 0.77 | DPP4 (0.89) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL3844850 | 0.77 | DPP4 (0.91) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL4116728 | 0.76 | DPP4 (0.69) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL3842519 | 0.76 | DPP4 (0.69) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL8297596 | 0.75 | DPP4 (0.65) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL12767537 | 0.75 | DPP4 (0.81) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL12767534 | 0.74 | DPP4 (0.65) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013068328-A1 | BICYCLO [2.2.2] OCTAN-1-YLCARBOXYLIC ACID COMPOUNDS AS DGAT-1 INHIBITORS | INTERVET INTERNATIONAL B.V. (NL) | 2013-05-16 | — | — | WO | disclosed |
| EP-1556362-B1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1684786-A4 | ENHANCEMENT OF GROWTH HORMONE LEVELS WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070123470-A1 | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue | MERCK & CO., INC. | 2007-05-31 | — | — | US | disclosed |
| US-7101871-B2 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1556362-A4 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1684786-A1 | ENHANCEMENT OF GROWTH HORMONE LEVELS WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1556362-A2 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005042003-A1 | ENHANCEMENT OF GROWTH HORMONE LEVELS WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. | 2004-12-16 | — | — | US | disclosed |
| WO-2004037169-A2 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037169-A2 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254167-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 4/4885DPP7 3/4885 |
| US-20070123470-A1 | Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue | DPP4, DPP3, GHSR | DPP4 1/4885DPP8 6/4885DPP7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.